ERBB2 and breast carcinoma: Despite the fact that Tra provides clinical benefit to patients with HER2 positive breast cancer, certain patients who initially respond acquire resistance within 24 to 36 months, suggesting the need to develop additional novel therapies targeting HER2 [10].